StocksMediumUpdated•Originally published 9 November 2026•Updated 9 November 2026•
1 min read
Neurogene Beats Q3 Earnings Estimates as J.P. Morgan Initiates Overweight Rating
Key Facts
1Neurogene reported Q3 earnings results that surpassed earnings per share (EPS) estimates.
2J.P. Morgan initiated coverage of the company's stock with an Overweight rating.
Neurogene reported a net loss of $29.0 million for the third quarter of 2026, even as its earnings per share results exceeded estimates. GuruFocus reported that J.P. Morgan initiated coverage of the company's stock with an Overweight rating.
The company maintains cash reserves of $359.7 million, which Neurogene expects will fund its operations into the first quarter of 2029. NGNE closed at $25.31 on November 6, 2026, after reaching a session high of $27.26.